Glutathione
Also known as: GSH, Reduced glutathione, γ-L-glutamyl-L-cysteinylglycine, L-γ-glutamyl-L-cysteinylglycine
3 notable studies · 4 references
TLDR
Glutathione is an endogenous tripeptide central to antioxidant defense, redox signaling and xenobiotic metabolism, with exceptionally strong evidence for its biological importance but much more variable evidence that administering additional glutathione produces meaningful clinical benefits, making endogenous glutathione biology and glutathione supplementation two evidence questions that should not be treated as equivalent.
Research Supports
- Studied for oxidative-stress defense and cellular redox regulation
- Investigated for xenobiotic detoxification via glutathione-conjugation pathways
- Studied for redox signaling through reversible protein S-glutathionylation
- Investigated for whether oral supplementation changes systemic glutathione status
- Studied in Parkinson's disease and skin-pigmentation/melanogenesis contexts
Observations Reported in Research
- Six-month trial (54 adults): glutathione increased in blood, erythrocytes, plasma and lymphocytes, especially at 1,000 mg/day (Richie et al., 2015)
- Four-week trial (40 adults): 500 mg twice daily produced no significant change in glutathione status or oxidative-stress biomarkers (2011)
- Small randomized Parkinson's trial (21 patients): IV glutathione was tolerated but UPDRS changes were not significantly different from placebo (Hauser et al., 2009)
- Reviews on skin pigmentation found modest, heterogeneous changes with durability concerns, and evidence for IV use was particularly weak
- The six-month oral trial also reported increased natural-killer-cell cytotoxicity at one time point in the higher-dose group
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Endogenous tripeptide; intracellular thiol antioxidant; redox regulator; detoxification substrate
Glutathione is an endogenous three-amino-acid peptide made from glutamate + cysteine + glycine. More precisely: γ-glutamyl-cysteinyl-glycine. It is one of the body's principal intracellular redox systems and participates in antioxidant defense, xenobiotic metabolism, maintenance of protein thiols and cellular signaling. That biology is extremely well established. What is much less straightforward is whether administering additional glutathione produces meaningful clinical benefits in people without a specific glutathione-related deficiency or disease state. Human supplementation studies are mixed. A 2011 randomized trial found no meaningful change in glutathione status or oxidative-stress biomarkers after four weeks of oral supplementation, while a six-month randomized trial later demonstrated significant increases in glutathione stores across several body compartments. That's exactly the distinction Aminodex should capture: Glutathione biology: extremely strong. Benefits of extra glutathione: route-, formulation-, population- and outcome-dependent.
What Is Glutathione?
Glutathione is unusual among small peptides because the glutamate-cysteine linkage uses glutamate's γ-carboxyl group rather than the conventional α-carboxyl linkage. Cells synthesize it in two ATP-dependent steps: Glutamate + cysteine → glutamate-cysteine ligase → γ-glutamylcysteine, then glycine → glutathione synthetase → Glutathione / GSH. Cysteine availability and glutamate-cysteine ligase activity are major determinants of glutathione synthesis. The reduced form is GSH while oxidation can generate GSSG — glutathione disulfide. The relationship between GSH and GSSG is an important component of cellular redox biology.
What Are Researchers Studying?
Oxidative stress
Glutathione participates directly in cellular defense against reactive oxygen species. Glutathione peroxidases can use GSH to reduce peroxides: 2 GSH + peroxide → GSSG + reduced peroxide product. Glutathione reductase can then regenerate GSH using NADPH. This creates a reusable intracellular redox system rather than glutathione functioning simply as a one-time free-radical sponge.
Detoxification
Glutathione participates in the metabolism of electrophilic xenobiotics through glutathione-conjugation pathways, including reactions catalyzed by glutathione S-transferases. That supports the legitimate statement: glutathione participates in cellular detoxification. It does not establish the much broader marketing statement: taking glutathione “detoxes the body.” Those are very different claims.
Redox signaling
Modern glutathione biology extends far beyond the simple “antioxidant” label. Glutathione can regulate proteins through S-glutathionylation, a reversible modification of protein cysteine residues involved in redox-sensitive cellular signaling. This means glutathione isn't merely cleaning up oxidants after they appear. It participates in the signaling systems cells use to respond to changes in oxidation state.
Oral bioavailability
This has produced apparently conflicting human findings. A randomized 2011 trial gave 40 healthy adults 500 mg twice daily for four weeks and found no significant changes in glutathione status or the measured oxidative-stress biomarkers. A later six-month randomized placebo-controlled trial involving 54 adults found increases in glutathione levels in blood, erythrocytes, plasma and lymphocytes, particularly with 1,000 mg/day. A small 2026 crossover study also investigated pharmacokinetic differences among standard, liposomal and micellar oral formulations, reinforcing that formulation may matter when discussing “oral glutathione” as though it were one intervention. So the best Aminodex wording is: Oral glutathione can alter glutathione status under some conditions, but bioavailability and physiological effects depend on formulation, exposure duration and the endpoint measured.
Parkinson's disease
Reduced glutathione levels and oxidative stress have long been investigated in Parkinson's disease. That prompted trials of exogenous glutathione. In a small randomized double-blind placebo-controlled trial, 21 patients were assigned IV glutathione or placebo for four weeks. Glutathione was tolerated, but UPDRS changes were not significantly different between groups. This is a useful Aminodex distinction: Altered glutathione biology in Parkinson's disease does not equal glutathione is an established Parkinson's treatment.
Skin pigmentation
Glutathione has also been investigated for effects on melanogenesis and pigmentation. A 2024 systematic review found some evidence of modest pigmentation changes with oral and topical glutathione, but studies were heterogeneous and durability was problematic. Evidence for IV glutathione was particularly weak. A 2026 review similarly concluded that evidence for skin-lightening effects remains limited and variable, especially for IV use. This shouldn't be reduced to: “Glutathione whitens skin.”
Immune function
Glutathione participates in immune-cell redox regulation and signaling. The six-month oral supplementation trial also reported an increase in natural-killer-cell cytotoxicity at one time point in the higher-dose group. That's interesting mechanistic/biomarker evidence. It does not establish glutathione as a general-purpose clinical “immune booster.”
How Does It Work?
There is no single glutathione receptor. Its biology includes several overlapping systems: Glutathione peroxidase → peroxide reduction; Glutathione reductase → regenerates reduced GSH from GSSG; Glutathione S-transferases → xenobiotic/electrophile conjugation; Protein glutathionylation → redox-sensitive signaling; GSH/GSSG balance → cellular redox regulation. So classifying glutathione merely as an “antioxidant peptide” actually understates its biology.
What Does the Research Show?
Human research
VERY HIGH for endogenous glutathione biology. HIGH for demonstrating that glutathione status changes in numerous disease states. MODERATE/MIXED for increasing systemic GSH through oral supplementation. LOW/INDICATION-DEPENDENT for treating specific diseases by administering glutathione. That separation matters enormously.
Animal research
EXTENSIVE. Glutathione synthesis, depletion, redox cycling, detoxification and disease-related changes have been studied across a huge range of animal models.
In-vitro research
EXTENSIVE / FOUNDATIONAL. Glutathione is among the best-characterized intracellular redox molecules in biology.
Notable Studies
Randomized Controlled Trial of Oral Glutathione Supplementation on Body Stores of Glutathione
humanFifty-four healthy nonsmoking adults received placebo, 250 mg/day or 1,000 mg/day oral glutathione for six months. Glutathione concentrations increased in several measured compartments, particularly in the high-dose group, and generally returned toward baseline after washout.
Limitations: Small healthy-adult study; biochemical increases do not establish improved health outcomes or treatment of disease.
View publication →Effects of Oral Glutathione Supplementation on Systemic Oxidative Stress Biomarkers in Human Volunteers
humanForty healthy adults received 500 mg glutathione twice daily or placebo for four weeks. Researchers found no significant between-group changes in glutathione status or the measured oxidative-stress biomarkers.
Limitations: Short intervention, small sample and healthy participants; doesn't exclude effects with longer exposure, different formulations or deficient/diseased populations.
View publication →Randomized, Double-Blind, Pilot Evaluation of Intravenous Glutathione in Parkinson's Disease
humanTwenty-one people with Parkinson's disease were randomized to IV glutathione or placebo. Treatment was tolerated, but differences in Parkinson's symptom scores were not statistically significant.
Limitations: Very small pilot study, four-week treatment period and inadequate power to establish clinical efficacy.
View publication →What We Still Don't Know
Which oral formulation most reliably alters intracellular GSH. How much increasing blood GSH reflects target-tissue changes. Whether raising GSH in already healthy people improves meaningful outcomes. Which diseases benefit from exogenous glutathione rather than precursor strategies. Long-term benefits of repeated exogenous administration. Which observed disease-associated GSH changes are causes versus consequences. Whether systemic GSH manipulation can sometimes interfere with useful redox signaling. Optimal biomarkers for assessing clinically relevant glutathione status.
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the Glutathione research with you.
Get the Aminodex Glutathione Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Lu SC. Glutathione synthesis. Biochim Biophys Acta. 2013.
- Xiong Y, Uys JD, Tew KD, Townsend DM. Glutathione synthesis and its role in redox signaling. 2011/2012.
- Richie JP Jr, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione.
- Hauser RA, et al. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease.
Supplier Listings
Disclosure: The owner of Aminodex operates the supplier(s) marked below. These listings are promotion for businesses we own, not independent recommendations. Read our disclosures.